ABAhmet Hüsamettin Baran

Ahmet Hüsamettin Baran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmet Hüsamettin Baran has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Repurposing Antidiabetic Agents as Potential Therapeutics in Neurodegenerative Diseases: Current Status and Future Perspectives

    by Ahmet Hüsamettin Baran

    This review focuses on preclinical, clinical, and epidemiological studies that demonstrate the therapeutic potential of antidiabetic drugs for the prevention and treatment of neurodegenerative diseases. Neurodegenerative disorders are a significant public health concern with a rising global prevalence. These conditions are progressive and heterogeneous, substantially reducing quality of life and imposing a considerable burden on healthcare systems and society. The increase in disability, morbidity, and mortality associated with these diseases occurs in parallel with the aging of the global population. Due to their complex etiology and progressive nature, neurodegenerative diseases present significant challenges in diagnosis and treatment. Current treatments are often limited to alleviating cognitive and/or motor symptoms and are largely insufficient in slowing, halting, or preventing disease progression. Consequently, there is an urgent need for novel therapies that can enhance neuronal function and impede the progression of underlying disease processes. Recent evidence from scientific studies has revealed important links between diabetes and neurodegenerative diseases. This review aims to guide future research by providing an up-to-date overview of the effects of antidiabetic agents on neurodegenerative diseases.

  • Open Access

    SILDENAFIL DECREASED TNF-α AND IL-6 LEVELS IN CD‐INDUCED ACUTE TOXICITY

    by Ahmet Hüsamettin Baran, Ahmet Berk, Ayşe Burçin Uyumlu, Özgen Arslan Solmaz, Göknur Yalım

    Objective: This study aimed to evaluate the effects of sildenafil (SIL) on inflammation and histopathological changes in cadmium (Cd)-induced toxicity in female rats. Material and Method: Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α) levels were measured to assess the degree of inflammation. Histopathological changes in the liver, lungs and kidneys were also assessed. Result and Discussion: SIL significantly reduced the cellular release of TNF-α and IL-6, which have been implicated in the pathogenesis of Cd-induced tissue damage. When SIL was administered alone, it showed histopathological effects similar to the control group. However, it was found that co-administration of SIL with Cd prevented portal vein dilation and central vein enlargement in the liver, prevented necrosis in kidney tissue, but did not affect the lung. Although SIL has variable protective effects on tissues, our results are in support of the idea that the use of SIL in tissue damage management can be investigated for its efficacy in modulating oxidative stress-induced proinflammatory cytokine activation in vivo and ultimately help prevent Cd-induced tissue damage. Our study has shown that SIL can reduce Cd-induced acute toxicity in rats. SIL may be use as a protective agent against toxicity of heavy metals.

  • A Promising Therapeutic Target in Neurodegenerative Diseases: Sestrin-2

    by Ahmet Hüsamettin Baran

    Alzheimer, Parkinson, Huntington ve amyotrofik lateral skleroz dâhil olmak üzere nörodejeneratif hastalıklar günümüz dünyasında giderek daha yaygın hale gelen, multifaktöriyel ve ilerleyici tipte hastalıklardır. Nörodejeneratif bozuklukların yaygın etiyolojilerinin başında yaşlanma, oksidatif stres ve mitokondriyal disfonksiyon gelmektedir. Nörodejeneratif hastalıkların tedavisinde kullanılan güncel ilaçlar hastanın yaşam kalitesini iyileştirse de hastalığın gelişimini ve ilerlemesini yavaşlatan veya önleyen bir tedavi henüz mevcut değildir. Bu ilaçların en büyük dezavantajı ise kronik kullanımlarında ciddi yan etkilerle karşılaşılmasıdır. Bu kapsamda yeni terapötik hedeflere yönelik uzun vadede yan etki profili düşük yeni ajanlara ihtiyaç duyulmaktadır. Son zamanlarda gerçekleştirilen çalışmalarda, stresle indüklenebilir bir metabolik protein olan Sestrin-2’nin reaktif oksijen türlerini baskıladığı, metabolizma ve inflamasyonu düzenlediği ve genotoksisite ve oksidatif stres, mitokondriyal disfonksiyon, endoplazmik retikulum stresi ve hipoksi dâhil olmak üzere çeşitli zararlı uyaranlara karşı hücresel koruma sağladığı gösterilmiştir. Sestrin-2’nin düzenlenmesi ve sinyal mekanizmalarına ilişkin çığır açan araştırmalarla, potansiyel rolü ve konak yanıtındaki önemi konusundaki bilgilerimiz önemli derecede artmış olsa da Sestrin-2’nin nörodejeneratif hastalıklarda işlevleri için daha fazla çalışmaya ihtiyaç duyulmaktadır. Bu çalışmada, nörodejeneratif hastalıklarda önemli bir terapötik hedef olma potansiyeline sahip Sestrin-2’ye dikkat çekmek amacıyla literatürdeki bilgiler detaylı bir şekilde derlenmiştir.